Nymox Pharmaceutical Corporation Appoints Erik Danielsen as Chief Financial Officer

Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company focused on developing its drug candidate, NX-1207, for treating benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The Company’s activities and resources have been directed primarily at developing certain pharmaceutical technologies. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company started two pivotal double-blind placebo-controlled Phase III trials for NX-1207, NX02-0017 and NX02-0018, conducted at investigational sites across the United States with a total enrollment of approximately 1,000 patients.